Therapeutic Perspectives for cN-II in Cancer.

Author(s): Lars Petter Jordheim, Laurent Chaloin.

Journal Name: Current Medicinal Chemistry

Volume 20 , Issue 34 , 2013

Become EABM
Become Reviewer

Abstract:

The cytoplasmic 5'-nucleotidase cN-II is involved in the regulation of endogenous pools of nucleosides and nucleotides together with nucleoside kinases and other intracellular enzymes. A series of results from studies on preclinical models and clinical samples constitutes the basis of the hypothesis in which cN-II is a therapeutic target in cancer. Indeed, the inhibition of its enzymatic activity seems interesting both to induce cell death directly and to increase the anticancer activity of cytotoxic agents used in cancer treatment. Here we will review the current knowledge of the enzymatic function of cN-II together with available structural data and the studies on cN-II in cancer cells and in samples from cancer patients. Recent and ongoing research on cN-II inhibitors is expected to confirm the druggability and the relevance of cN-II as a cancer drug target. Preliminary in vitro data and cancer cell models using cN-II inhibitors have already suggested the pivotal role of this enzyme as therapeutic target allowing the improvement of anticancer treatments.

Keywords: Cell models, clinical trials, cN-II, crystallography, enzymatic assay, inhibitor, virtual screening.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 34
Year: 2013
Page: [4292 - 4303]
Pages: 12
DOI: 10.2174/0929867311320340008
Price: $58

Article Metrics

PDF: 15